Refracture and mortality following hospitalization for severe osteoporotic fractures: The Fractos Study

JBMR Plus

Florence Tubach¹  Christian Roux²  Thierry Thomas³  Julien Paccou⁴  Magali Lemaitre⁵  Geoffray Bizouard⁵  Frédérique Maurel⁵  Anne Crochard⁶  Laure Perrin⁶  Emese Toth⁶ 

[1] Department of Public Health, Pharmacoepidemiology Center (Cephepi) Sorbonne University, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP‐HP Sorbonne University, Pitié‐Salpêtrière Hospital, CIC‐1422 Paris France;Department of Rheumatology Cochin Hospital, Assistance Publique ‐ Hôpitaux de Paris Centre, Institut National de la Santé et de la Recherche Médicale (INSERM) Unités Mixtes de Recherche (UMR) 1153, Université de Paris Paris France;Department of Rheumatology Hôpital Nord, Centre Hospitalier Universitaire (CHU) Saint‐Etienne, INSERM U1059, Lyon University Saint‐Etienne France;Department of Rheumatology Lille University, CHU Lille, Marrow Adiposity and Bone Laboratory (MABlab) ULR 4490 Lille France;IQVIA Courbevoie France;UCB Pharma Colombes France;

关键词: OSTEOPOROSIS;    GENERAL POPULATION STUDIES;    FRACTURE RISK ASSESSMENT;    FRACTURE PREVENTION;    THERAPEUTICS;   

DOI  :  10.1002/jbm4.10507

来源: DOAJ

【 摘 要 】

ABSTRACT Severe osteoporotic fractures (hip, proximal humerus, pelvic, vertebral and multiple rib fractures) carry an increased risk of mortality. This retrospective cohort study in the French national healthcare database aimed to estimate refracture and mortality rates after severe osteoporotic fractures at different sites, and to identify mortality‐related variables. A total of 356,895 patients hospitalized for severe osteoporotic fracture between 2009 and 2014 inclusive were analyzed. The cohort was followed for 2 to 8 years up to the study end or until the patient died. Data were extracted on subsequent hospitalizations, refracture events, treatments, comorbidities of interest and survival. Time to refracture and survival were described using Kaplan‐Meier analysis by site of fracture and overall. Mortality risk factors were identified using a Cox model. Hip fractures accounted for 60.4% of the sample (N = 215,672). In the 12 months following fracture, 58,220 patients (16.7%) received a specific osteoporosis treatment, of whom 21,228 were previously treatment‐naïve. The 12‐month refracture rate was 6.3% (95% confidence interval [CI], 6.2%–6.3%), ranging from 4.0% (95% CI, 3.7%–4.3%) for multiple rib fractures to 7.8% (95% CI, 7.5%–8.1%) for pelvic fractures. Twelve‐month all‐cause mortality was 12.8% (95% CI, 12.7%–12.9%), ranging from 5.0% (95% CI, 4.7%–5.2%) for vertebral fractures to 16.6% (95% CI, 16.4%–16.7%) for hip fractures. Osteoporosis‐related mortality risk factors included fracture site, previous osteoporotic fracture (hazard ratio 1.21; 95% CI, 1.18–1.23), hip refracture (1.74; 95% CI, 1.71–1.77), and no prior osteoporosis treatment (1.24; 95% CI, 1.22–1.26). Comorbid cancer (3.15; 95% CI, 3.09–3.21) and liver disease (2.54; 95% CI, 2.40–2.68) were also strongly associated with mortality. In conclusion, severe osteoporotic fractures, including certain non‐hip nonvertebral fractures, carry a high burden in terms of mortality and refracture risk. However, most patients received no anti‐osteoporotic treatment. The findings emphasize the importance of better management of patients with severe fractures, and of developing effective strategies to reduce fracture risk in patients with osteoporosis. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

【 授权许可】

Unknown